بسم الله الرحمن الرحيم

شبكة المعلومـــــات الجامعية

التوثيق الالكتروني والميكروفيلم

شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الالكتروني والميكروفيلم

﴿ قـــسـم ﴾

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأفلام قد اعدت دون آية تغيرات

يجب أن

تحفظ هذه الأفلام بعيداً عن الغبار

في درجة حرارة من 15 – 20 مئوية ورطوبة نسبية من 20-40 %

To be kept away from dust in dry cool place of
15 – 25c and relative humidity 20-40 %

بعض الوثائق الأصلية تالفة

بالرسالة صفحات

لم ترد بالأصـــل

Faculty of Medicine

Treatment of Leprosy

THESIS

Submitted for Partial Fulfilment for master Degree in Dermatology, Venereology and Andrology

By

Abdel-Wasea Mohamed Al- Mekhlafi

(M.B.B.ch)

SUPERVISED BY

Professor: **Dr. Ahlam Abdel-Latif Fahmi**

Professor of Dermatology, Venereology and Andrology

Dr. Nagwa Essa Abd-el-Azem

Assis.Professor of Dermatology, Venereology and Andrology

Faculty of Medicine

Assiut University

2000

ACKNOWLEDGEMENT

I wish to express my deepest gratitude to professor Dr. Ahlam Abdel-Latif Fahmi, professor of Dermatology, venereology and Andrology, Faculty of Medicine, Assuit University, for her kind advice, helpful guidance, great support and encouragement and also for her remarks and precious instructions during all steps towards fulfilling this work.

I wish also to express my deepest appreciation to Dr. Nagwa Essa Abdel-Azem, Assistant Professor of Dermatology, venereology and Andrology, Faculty of Medicine, Assiut University, for her close and also for the valuable effort and time she spent so generously in guiding and leading me during this work.

I would like to thanks Prof. Dr. Kamal Abdel-Hafez Head of department of Dermatology, venereology and Andrology, for his support. My thanks and best wishes of health for him.

I am also grateful to all staff members for their cooperation and encouragement. Also for collegues in the department of Dermatology, venereology and Andrology, Faculty of Medicine, Assuit Univeristy, for their cooperation and help.

Abdel wasea Al-Mekhlafi

2000

List of Abbreviations

BB =	Borderline Leprosy.
BI =	Bacterial index.
BL =	Borderline Lepromatous Leprosy.
BT =	Borderline tuberculoid leprosy.
CD =	Clusters of differentiation
CD4 =	helper-T-cell subsets.
CD8 =	suppressor/cytotoxic-T cell subsets.
DTH =	delayed type hypersensitivity.
ENL =	Erythema Nodosum leprosum.
HIV =	Human Immunodeficiency virus.
I =	Indeterminate.
IFN =	Interferon.
IGg =	Immunoglobulin.
IL =	Interleukin.
LL =	Lepromatous Leprosy.
MB =	Multibacillary.
MDT =	Multidrug therapy.
MIC =	Minimal inhibitory concentration.
NFI =	Nereve function impairment.
PB =	Paucibacillary.
PGL =	Phenolic glycolipid.
POP =	Plaster of paris.

PYAR =	Patient years at risk.
ROM =	Rifampicin, Ofloxacin and Minocycline.
RR =	Reversal reaction.
SLPB =	Single lesion paucibacillary.
TNF =	Tumour Necrosis factor.
TT =	Tuberculoid Leprosy.
VMT =	Voluntary motor testing.
WHO =	World Health Organization.

Contents

INTRODUCTION

INTRODUCTION AND AIM OF THIS REVIEW

Leprosy is an infectious disease caused by Mycobacterium leprae, which is a slow-growing intracellular bacillus that infiltrates the skin, the peripheral nerves, the nasal and other mucosa, and eyes. The incubation period between infection and appearance of leprosy is normally between two and 10 years but may be as long as 20 years. Leprosy can affect all ages and both sexes.

Humans infected with leprosy are the primary reservoir. Close and prolonged contact within the household is a significant factor in the transmission of disease. Leprosy infection probably occurs when Leprosy bacteria are discharged through the nose. Leprosy is transmitted to a previously uninfected person when nasal secretions from a M. Leprae infected leprosy patient contaminate the nasal mucosa or minor skin abrasions of the previously uninfected person. However, most individuals have considerable natural immunity and many infections are suppressed. Leprosy cases seldom develop in non endemic areas without known close contacts.

Protective immune response in leprosy is based on cellular immune response and leprosy bacilli are killed or eliminated only by this mechanism (Noordeen and Pannikar, 1996).

Leprosy (Hansen's disease) presents a broad spectrum of clinical and histopathological manifestation which reflect the nature of individual's immune response to mycobacterium leprae.

This spectrum of clinical manifestation include two polar types of infection, lepromatous leprosy (LL) and tuberculoid leprosy (TT) as well as intermediate borderline forms of disease (Ridley and Jopling, 1966).

To simplify field work, the World Health Organization (WHO) classifies leprosy patients according to the bacillary load as multibacillary (MB) patients, with an elevated bacterial load, and paucibacillary (PB) patients, who presents negative or weak bacilloscopy (Rada et al, 1996). The paucibacillary (PB) group included all polar tuberculoid (TT), borderline tuberculoid (BT) and indeterminate (I) cases.The multibacillary (MB) group consists of polar lepromatous (LL), borderline lepromatous (BL) and mid-borderline (BB) patients.

Tissues infected with mycobacterium leprae contain large amounts of phenolic glycolipid 1 (PGL-1) which is a highly specific antigen of the microorganism. Antibody levels against PGL-1 are frequently used to follow up the therapeutic response and elemination of the bacillary load in patients under treatment (Bach et al, 1988, Chanteau et al, 1989 and Meeker et al, 1990).

Because of the bacterial resistance induced by mono drug therapy, it has been necessary to develop and implement effective multidrug treatment of leprosy patients (Convite et al, 1986; Waters, 1993).

Leprosy produces disability and deformity through nerve damage. Type 1 reactions (reversal reactions) are generally known to be a major cause of nerve damage in borderline leprosy (BL) patients (Job, 1989).

Leprosy can cause damage to the cranial nerves and to many peripheral nerve trunks which leads to visible paralytic deformities (sugumaran, 1996).

Visual impairment or blindness is a frequent complication of leprosy. Blindness results either from mycobacterial infiltration and inflammation of structures in the anterior segment of the eye or from

trophic changes following damage to the trigeminal and facial nerves, resulting in lagophthalmos, deformed or corneal anesthesia (WHO, 1998,a)

The aim of this review is to highlighten the various drugs and drug combinations which can be used in the treatment of different types of leprosy and leprae reactions, and deformities to assess their effectiveness and their possible side effects.